Skip to main content

Table 3 Results related to the changes in the diary-based symptoms in the study groups

From: A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome

Variable Group Baseline Week 8 Mean difference
BSFS
Median,(IQR)
Intervention 5.50 (6–5.07) 4.00 (4.5–3.5) −1.25(− 0.8-(− 1.9))
Control 5.35 (5.8–5) 5.00 (5.5–4.5) − 0.30 (0.2-(− 0.6))
P- value 0.34 < 0.001 < 0.001
Bowel frequency per day
Mean ± SD
Intervention 2.30 ± 0.69 1.83 ± 0.43 − 0.48 ± 0.41
Control 2.27 ± 0.63 2.15 ± 0.57 − 0.12 ± 0.31
P- value 0.79 0.01 < 0.001
Abdominal pain score
Mean ± SD
Intervention 1.50 ± 0.45 0.97 ± 0.45 − 0.54 ± 0.41
Control 1.65 ± 0.62 1.44 ± 0.58 − 0.21 ± 0.37
P- value 0.27 < 0.001 0.001
Urgency score
Mean ± SD
Intervention 1.70 ± 0.48 1.13 ± 0.47 − 0.57 ± 0.33
Control 1.57 ± 0.57 1.41 ± 0.53 − 0.16 ± 0.29
P- value 0.31 0.03 < 0.001
Bloating score
Mean ± SD
Intervention 1.61 ± 0.57 1.38 ± 0.39 − 0.25 ± 0.43
Control 1.51 ± 0.57 1.32 ± 0.50 − 0.19 ± 0.35
P- value 0.47 0.69 0.54
Days with urgency
Median,(IQR)
Intervention 5.00 (6–4) 4.00 (5–3) − 2.00 (0.00- (− 2))
Control 6.00 (6–4) 5.00 (6–3) 0.00 (0.00- (− 2))
P- value 0.36 0.01 0.05
Days with pain
Median,(IQR)
Intervention 5.00 (6–4) 3.00 (4–2) − 2.00 (− 1-(− 2))
Control 5.00 (5.5–4) 5.00 (5–3.5) 0.00 (0.00- (− 1))
P- value 0.75 < 0.001 < 0.001
Days with diarrhea
Median,(IQR)
Intervention 5.00 (6–4) 4.00 (4–2.75) − 1.50 (0.75- (− 2.25))
Control 5.00 (6–4) 4.00 (5–4) 0.00 (0.00- (− 2))
P- value 0.84 0.001 0.003
Days with bloating
Median,(IQR)
Intervention 6.00 (7–5) 5.00 (6–3.75) − 1.00 (0.00- (− 2))
Control 5.00 (7–4.5) 5.00 (6–4) − 1.00 (1- (− 1.5))
P- value 0.59 0.17 0.11
  1. BSFS Bristol Stool Form scale, IQR Interquartile range, SD Standard deviation